When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload?
Date
2012
Authors
Bird, R.
Kenealy, M.
Forsyth, C.
Wellwood, J.
Leahy, M.
Seymour, J.
To, L.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Internal Medicine Journal, 2012; 42(4):450-455
Statement of Responsibility
R.J. Bird, M. Kenealy, C. Forsyth, J. Wellwood, M.F. Leahy, J.F. Seymour and L.B. To
Conference Name
Abstract
Despite the absence of a robust evidence base, there is growing consensus that effective treatment of iron overload leads to decreased morbidity and premature mortality in patients with good prognosis myelodysplastic syndromes (MDSs). Furthermore, new treatment modalities, including disease-modifying therapies (lenalidamide and azacytidine) and reduced intensity conditioning therapies for allogeneic blood stem cell transplants, are offering the prospect of longer survival for patients with traditionally less favourable prognosis MDS, who might also benefit from iron chelation. This article proposes assessment of patients with MDS and related bone marrow failure syndromes to determine suitability for iron chelation. Iron chelation therapy options and monitoring are discussed.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2012 The Authors. Internal Medicine Journal © 2012 Royal Australasian College of Physicians